Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board approved allotment of 33,27,778 equity shares at Rs. 30.05 per share (Rs. 10 face value + Rs. 20.05 premium), raising about Rs. 10 crore via preferential basis to 13 individual investors. The Board also approved issuance of secured, unlisted, unrated NCDs up to Rs. 10 crore. For FY25, the company reported strong growth: AUM nearly doubled to Rs. 255.56 crore (up 96.6%), total income rose 85% to Rs. 47.92 crore, and net profit jumped 120% to Rs. 1.21 crore. Branch network expanded from 53 to 76. Capital adequacy stood healthy at 32.31% with gross NPA contained at 0.79%. Statutory auditors issued an unmodified opinion.
The Rs. 10 crore equity infusion strengthens the company's capital base, supporting its aggressive branch expansion and lending growth. Existing shareholders face dilution of about 10% (33.27 lakh new shares vs ~3 crore existing), but the strong FY25 results and low NPA signal healthy fundamentals, likely supportive of the stock in the short term.